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Ventricular tachyarrhythmias associated with digitalis
toxicity are believed to be due, in part, to cardiac gly-
coside-mediated increased central sympathetic neural
activity. Becausedopaminergic receptor agonists reduce
sympathetic outflow, this study assessed effectiveness of
the available dopaminergic agonist, bromocriptine, in
slowing or terminating ouabain-induced ventricular
tachycardia in anesthetized dogs. In all experiments,
ouabain was administered intravenously (20ltg/kg body
weight bolus injection, followed by 2.5 Itg/kg per min
infusion) until the onset of stable ventricular tachycardia.
Of seven untreated dogs (Group 1), ouabain-induced
ventricular tachyarrhythmias resulted in ventricular fi-
brillation in three, while in four dogs tachycardia per-
sisted without significant change in rate until the study
was terminated. Fourteen dogs (Group 2) received
bromocriptine, either 30 ltg/kg (Group 2A)or 50 ltg/kg
---_._--_..__._----_..._-------
Ventricular tachyarrhythmias are an important manifestation
of digitalis toxicity and are believed to be, in part, the result
of cardiac glycoside-mediated increased sympathetic ner-
vous system outflow (1-8). Potentially, direct pharmacol-
ogic reduction of sympathetic neural activity, such as may
be achieved by administration of doparninergicagonists (1-9),
can become a useful therapeutic tool for preventing life-
threatening digitalis-induced ventricular tachyarrhythmias.
---_.._---
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(Group 2B), after the onset of ventricular tachycardia.
Tachycardia slowed in all 14 dogs and terminated with
resumption of sinus rhythm in 8 of the 14. In all six dogs
pretreated with the peripheral dopaminergic antagonist
domperidone (Group 3), bromocriptine,50 ltg/kg, slowed
ventricular tachycardia and in three of the six, tachy-
cardia terminated. In contrast, of five dogs pretreated
with haloperidol, a central and peripheral dopaminergic
receptor antagonist (Group 4), bromocriptine, 50 ltg/kg,
failed to slow ventricular tachycardia in three, and two
of the three developed ventricular fibrillation.
In summary, the dopaminergic receptor agonist,
bromocriptine, presumably acting at central dopami-
nergic receptor sites, consistently slowed and in most
cases reversed ouabain-induced ventricular tachycardia
in a canine model.
-----_ .._---
Bromocriptine is a dopaminergic agonist approved in the
United States for treatment of endocrine disorders resulting
in hyperprolactinemia (10,11). The principal purpose of this
study was to determine whether bromocriptine administra-
tion is capable of reversing ouabian-induced ventricular
tachyarrhythmias. In addition, this study attempted to de-
termine whether the antiarrhythmic action of bromocriptine
is due primarily to peripheral or central dopaminergic re-
ceptor agonist activity by attempting to block the protective
action of bromocriptine with either a selective peripheral
(domperidone) (10) or a combined peripheral and central
(haloperidol) (12) dopaminergic blocking agent.
Methods
Experimental preparation. Thirty-six mongrel dogs of
either sex, ranging in weight from 19 to 37 kg (mean 25),
were studied in four groups of experiments. All dogs were
anesthetized with pentobarbital sodium (30 mg/kg intrave-
nously). Oxygenation was maintained using positive pres-
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sure ventilation (Harvard model 607 respirator) with room
air through a cuffed endotracheal tube . The right femoral
artery and vein were cannulated with standard polyethylene
catheters . Systemic blood pressure was measured using a
Statham P23AA transducer and recorded on a multichannel
recorder (Electronics for Medicirie model DR 12). A 4F bi-
polar electrode catheter was introduced by percutaneous
puncture of the right internal jugular vein and advanced into
the right atrium , and both a right atrial electrogram and lead
III electrocardiogram were monitored continuously through-
out the study. Recordings were obtained at paper speeds of
25 to 50 mm/s and data were digitized and analyzed using
an interactive computerized system .
Experimental protocol. In all dogs, ouabain (Eli Lilly)
was administered as a bolus intravenous injection (20 iLg/kg),
followed \0 minutes later by continuous intravenous infu-
sion (2.5 iLg/kg per min) through the femoral venous cath-
eter ( I :1). Ouabain infusion was discontinued after initiation
of sustained ventricular tachycardia.
In .\'tven dogs (Group I . control group) , the duration of
ouabain -induced ventricular tachycardia was used to assess
the effi cacy of drug interventions in dogs in Groups 2, 3
and 4.
In the 14 dogs in Group 2, after the initiation of ven-
tricular tachycardia, an observation period of 20 to 30 min-
utes was allowed to ensure the presence of a stable sustained
tachyarrhythrnia. Bromocriptine (Sandoz, Inc.) was then in-
fused intravenously (l iLg/kg per min) for either 30 or 50
minutes (that is, a total dose of 30 or 50 iLglkg). In these
studies , bromocriptine was dissolved in 2 ml of ethanol
(95%) and diluted in normal saline solution to result in a
solution of 1 iLg/ml. After completion of bromocriptine
infusion, electrocardiographic and femoral artery pressure
recordings of I minute's duration were obtained every 10
minutes for the duration of the experiment. In experiments
in which ventricular tachycardia terminated after bromo-
criptine treatment, time of conversion to sinus rhythm was
noted and the subsequent cardiac rhythm was recorded for
a minimum of 10 minutes to ensure that sinus rhythm was
stable .
The six dogs in Group 3 were pretreated with a bolus
injection of domperidone (Janssen Pharmaceutica), a pe-
ripheral dopaminergic antagoni st (10) . Domperidone was
prepared by dissolving 0.5 rng/kg in I cc of 0 .\0 M lactic
acid and diluted to 10 cc with normal saline solution . Thirty-
five minute s after domperidone injection , the ouabain bolus
injection and infusion protocol was initiated as described in
the dogs in Groups I and 2. After onset of stable ventricular
tachycardia, bromocriptine was infused intravenously ( I iLglkg
per min) for 50 minutes. Cardiac rhythm, systemic arterial
pressure and the time of conversion to sinus rhythm in those
dogs in which ventricular tachycardia terminated were re-
corded as described previously.
Nine dogs in Group 4 were pretreated with haloperidol,
0.75 to I mg/kg (McNeil Pharmaceutical), a dopaminergic
antagonist with both central nervous system and peripheral
activity (12). Haloperidol was infused for 15 minutes in the
initial six dogs and for 30 minute s in the remaining three
dogs. Ten minutes after completion of the haloperidol in-
fusion, the ouabain bolus injection and infusion protocol
was initiated as before. Only five of the nine dogs survived
the combined haloperidol-ouabain infusion , and in these five
dogs bromocriptine infusion ( I iLg/kg per min) was initiated
20 minutes after onset of stable ventricular tachycardia.
Cardiac rhythm and systemic arter ial pressure recordings
were monitored and recorded as described previously .
Data analysis. The equality of mean values of ventric-
ular tachycardia cycle length before and after bromocriptine
administration were analyzed using the Student's paired t
test. Temporal effects of drug therapy on ventricular tachy-
cardia cycle length were examined by both nonlinear and
linear regression analysis techniques to obtain a best fit
approximation . A probability of less than 0 .05 was consid -
ered statistical significance .
Definition. Sustained ventricular tachycardia was de-
fined to be present if a wide QRS tachycardia complex (cycle
length < 400 ms) with atrioventricular dissociation persisted
throughout a 20 to 30 minute observation period after ter-
mination of the ouabain infusion .
Results
Duration of untreated ouabain-induced ventricular
tachycardia (Group 1). In three of the seven untreated
control dogs in Group I , ouabain-induced ventricular tachy-
cardia degenerated into ventricular fibrillation within 15 to
210 minutes of the onset of tachycardia. In the remaining
four dogs, ventricular tachycardia continued to be present
at 235 ± 35 minutes, when the experiments were termi-
nated . During the latter observation period, there was no
significant change in ventricular tachycardia cycle length
(273 ± 25 ms at onset versus 280 ± 35 ms at the end of
study, P = NS). In addition , there was no apparent tendency
toward normalization of the cardiac rhythm (that is, the
percent of QRS complexes of ventricular tachycardia origin
remained 100% throughout) .
Effect of Bromoeriptine on Ouabain-Induced
Ventricular Tachycardia
Of the 14 dogs in Group 2,7 (Group 2A) received brom-
ocriptine , 30 iLglkg, and 7 (Group 2B) received bromo-
criptine, 50 iLg/kg.
Group 2A (bromocriptine, 30 ltg/kg). In four of the
seven dogs, ventricular tachycardia terrriinated and sinus
rhythm resumed within 60 to 180 minutes after completion
ofbromocriptine infusion . In the three remaining dogs, ven-
tricular tachycardia was still present at termination of the
experiments (250, 280 and 260 minutes after completion of
bromocriptine infusion, respectively). In all seven dogs,
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ventricular tachycardia cycle length prolonged significantly
within the first 100 minutes after bromocriptine infusion
(330 ± 53 ms, compared with the period before the infu-
sion, 268 ± 14 ms, p < 0.01) (Fig. 1). Bromocriptine-
induced ventricular tachycardia cycle length prolongation
(time zero defined as the end of bromocriptine infusion) was
Best approximated by a linear regression line (Fig. 2).
In three of the four dogs in which ventricular tachycardia
tfrminated, the conversion to sinus rhythm was abrupt. In
the fourth dog, a gradual increase in the number of sinus
beats was observed before conversion to stable sinus rhythm.
In the three dogs in which ventricular tachycardia did not
terminate, ventricular tachycardia beats continued to con-
stitute 100% of the cardiac rhythm despite slowing of the
ventricular tachycardia rate.
Group 2B (bromocriptine, 50 ltg/kg). Ventricular
tachycardia terminated with resumption of sinus rhythm in
Figure 1. Graph illustrating the temporal effect of bromocriptine
administration on slowing ventricular tachycardia (VT) in dogs in
Group 2. Findings in seven dogs in Group 2A (bromocriptine, 30
JLg/kg) are depicted by hatched lines and open circles, whereas
findings in seven dogs in Group2B (bromocriptine, 50 JLg/kg) are
indicated by solid lines and closed circles. Ventricular tachycardia
cycle length is indicated on the ordinate in milliseconds and time
(minutes) after completion of bromocriptine infusion is On the
abscissa. Asterisks mark those experiments in which ventricular
tachycardia did not terminate during the course of the post-bromo-
criptine monitoring period. C = control.
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four of the seven dogs within 20 to 120 minutes after com-
pletion of brornocriptine infusion. In two of the three dogs
in which ventricular tachycardia did not terminate, the mon-
itoring period after bromocriptine infusion was only 60 to
80 minutes in duration.
Within the first 100 minutes after bromocriptine infusion,
significant prolongation of ventricular tachycardia cycle
length (in dogs in which ventricular tachycardia had not
terminated) occurred (bromocriptine: 357 ± 44 ms versus
pre-bromocriptirie control: 277 ± 20 ms, p = 0.002) (Fig.
I). Again, a linear regression equation (time zero defined
as the end of bromocriptine infusion) best approximated
bromocriptine-induced ventricular tachycardia cycle length
prolongation (Fig. 2).
In each of the four dogs in which ventricular tachycardia
Figure 2. Graph depicting the temporal effect of bromocriptine
treatment on ventricular tachycardia cycle length in dogs in Group
2. The ordinate indicates ventricular tachycardia cycle length, and
the abscissa ihdicates the time in minutes after completion of
brornocriptine infusion. For dogs in Group 2A (hatched lines and
open circles) the best fit regression line is described by the equa-
tion: ventricular tachycardia cycle length = 272 + 0.37t (p =
0.6001), where t = time in minutes. For dogs in Group 2B (solid
line and closed clrcles). the best fit regression line is described
by the equation: ventricular tachycardia cycle length = 289 +
O.72t (p < 0.0025). Data points are mean ± I standard deviation.
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Figure 3. Recordings showing theeffect of bromocriptine admin-
istration . 50 JLglkg, in a dog in Group 2B. From top to bottom
in each panel, recordings areelectrocardiographic (ECG) lead III,
intraatrial electrogram (At EG) and aortic (Ao) pressure. Panel
A, Baseline sinus rhythm (cycle length (CL] 480 ms) . Panel B,
Ventricular tachycardia recording 10 minutes aftercompletion of
ouabain infusion (cycle length 300 ms). Panel C, Ventricular
tachycardia recording 55 minutes after completion of bromocrip-
tine infusion illustrating progressive slowing of tachycardia rate
(cycle length 370ms). Panel D, At 118 minutes aftercompletion
of brornocriptine infusion, ventricular tachycardia cycle length
(left) slowed further to 400 ms. Abrupt termination of tachycardia
with resumption of sinus rhythm is shown at right (arrow). Note
that sinus cycle length afterventricular tachycardia conversion (900
ms) is slower than control sinus cycle length (panel A) consistent
with reduced sympathetic neural activity.
terminated, the conversion to sinus rhythm was abrupt (Fig.
3). In the three dogs in which tachycardia did not terminate,
there was no apparent reduction in the percent of QRS
complexes of ventricular origin despite tachycardia slowing.
Time course of ventricular tachycardia termination after
bromocriptine infusion. Figure 4 summarizes the time course
of the effect of bromocriptine on terminating ventricular
tachycardia in dogs in Groups 2A and 28 . Linear regression
analysis best approximated the temporal effects of bromo-
criptine on tachycardia termination, and indicated that there
was a significant difference in the proportion of dogs re-
marrung in ventricular tachycardia over time in the two
dosage groups (p = 0.043) . From this analysis, ventricular
tachycardia termination would be expected to be effected
in 50% of animals at approximately 160 minutes for dogs
in Group 2A (30 ILg/kg) and 92 minutes for dogs in Group
2B (50 ILg/kg).
Group 3: Effect of bromocriptine in domperidone-
pretreated ouabain-toxic dogs. Bromocriptine, 50 ILg/kg,
terminated ouabain-induced ventricular tachycardia in three
of the six dogs in Group 3 at 112 ± 22 minutes after
completion of infusion. In dogs remaining in ventricular
tachycardia at 120 minutes after completion of bromocrip-
tine infusion, ventricular tachycardia cycle length had pro-
longed significantly from a pre-bromocriptine value of 252
± 28 ms to a post-brornocriptine value of 353 ± 105 ms
(p < 0.05) (Fig. 5). Regression analysis of ventricular
tachycardia cycle length of dogs in Group 3 yielded a linear
relation between cycle length and time (zero time defined
as the end of brornocriptine infusion) (Fig. 5).
Of the three dogs pretreated with domperidone in which
ventricular tachycardia terminated , conversion to sinus
rhythm was abrupt in one (Fig. 6) and gradual in the other
two (that is, the percent of ventricular tachycardia beats
progressively decreased before the termination of ventricular
tachycardia). In the three dogs whose arrhythmia failed to
convert to sinus rhythm, the percent of ventricular tachy-
cardia beats remained 100% throughout the study.
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Figure 5. Graph illustrating the temporal effect of bromocriptine
(50 ILg/kg) on cycle length of ventricular tachycardia in Group 3
domperidone-pretreated dogs. Ventricular tachycardiacycle length
is indicated on the ordinate (ms) and time (min) after bromocrip-
tine infusion is depicted on the abscissa. There was no significant
difference between the effect of bromocriptine on ventricular
tachycardia cycle length in domperidone-pretreated Group 3 and
nonpretreated Group 28 dogs. The best fit regression line describ-
ing ventricular tachycardia (VT) cycle length changes in dogs in
Group 3 was: VT cycle length = 253 + O.77t (t = time in
minutes).
450
bromocriptine-induced hypotension (mean systemic pres-
sure decrease, 48 ± 45 mm Hg).
Discussion
In this study, bromocriptine, a clinically available do-
paminergic agonist, consistently slowed and in 8 of 14 dogs
(Groups 2A and 2B) abruptly terminated ouabain-induced
ventricular tachycardia. Two bromocriptine doses were as-
sessed (30 and 50 JLg/kg). The higher dose had a more
pronounced effect on slowing ventricular tachycardia rate
(Fig. 3) and resulted in earlier ventricular tachycardia ter-
mination (Fig. 4) without a significant increment in the
degree of drug-induced hypotension. Furthermore, the ther-
apeutic effectiveness of bromocriptine in these studies was
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Figure 4. Graph illustrating the temporal effect of bromocriptine
on ventricular tachycardia conversion to sinus rhythm in dogs in
Group 2. Dogs in Group 2A (30 ILg/kg) are indicated by hatched
lines and open circles, whereas dogs in Group 28 (50 ILg/kg) are
indicated by solid lines and closed circles. The ordinate depicts
the percent of dogs in ventricular tachycardia at a given time, and
the abscissa indicates the time (min) after completion of bromo-
criptine infusion. There is a statistically significant difference (p
= 0.043) in the temporal effectiveness of the two bromocriptine
doses in terminating ventricular tachycardia. The best fit regression
lines for the number of dogs remaining in ventricular tachycardia
at time (t) are: Group 2A: y = 6.99 - 0.022t (r = 0.96, P <
0.00l) and Group 28: y = 6.87 - 0.036t (r = 0.87, P < 0.001),
where y = number of dogs remaining in ventricular tachycardia
at time t, and t = time in minutes after completionofbromocriptine
infusion.
Comparison of ventricular tachycardia cycle length pro-
longation in dogs in Group 2B and Group 3 was performed
using Student's t test assuming equal and unequal variances,
and was not found to differ significantly by either analysis
technique. Furthermore, the slopes of the linear regression
equations describing ventricular tachycardia slowing in dogs
in Groups 2B and 3 were not statistically different.
Group 4: Effect of bromocriptine on haloperidol-pre-
treated ouabain-toxic dogs. In four of the nine Group 4
dogs pretreated with haloperidol, ventricular fibrillation oc-
curred during ouabain infusion, but before administration
of bromocriptine, 50 JLg/kg; these dogs were excluded from
further analysis. Of the five remaining dogs in Group 4,
ventricular tachycardia terminated in two animals (at 150
and 190 minutes after bromocriptine, respectively) but failed
to terminate in the remaining three animals. Two of the
latter three dogs developed ventricular fibrillation despite
bromocriptine treatment; before haloperidol administration
this arrhythmia had not occurred in animals treated with
bromocriptine.
Effect of bromocriptine infusion on systemic blood
pressure. In dogs in both Groups 2A and 2B, bromocrip-
tine infusion resulted in significant decreases (45 ± 31 and
50 ± 33 mm Hg, respectively) of mean systemic pressure
from control values (p < 0.01). Similarly, in dogs in Groups
3 and 4, neither domperidone nor haloperidol prevented
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Figure6. Recordings (lead III electrocardiogram and aortic pres-
sure) illustrating abrupt terminationof ventricular tachycardia 110
minutes after completion of bromocriptine infusion in a dornper-
idone pretreated dog. The ventricular tachycardia cycle length in
this animal before bromocriptine infusion was 258 ms. Sixty min-
utes after bromocriptine infusion, the ventriculartachycardiacycle
length was272 ms, and at 110minutes (left) the ventriculartachy-
cardia cycle length was 290 ms. Terminationof ventricular tachy-
cardia (arrow)was followed by resumption of stablesinus rhythm.
unaltered by administration of the predominantly periph-
erally acting dopaminergic receptor antagonist, dornperi-
done ( 10). In contrast, after pretreatment of dogs with halo-
peridol (a dopaminergic receptor antagonist that acts both
centrally and peripherally) (12), the effcctiveness of bromo-
criptine was diminished . Thus , our findings suggest both
that brornocriptine may be a useful antiarrhythmic agent for
treatment of digitalis-induced tachyarrhythmias, and that in
this context the principal site of action of bromocriptine is
at central dopaminergic receptors .
Role of increased sympathetic neural activity in oua-
bain toxicity. Recent investigations suggest that the de-
veloprncnt of ouabain-induced ventricular tachyarrhythmias
is, in part, the result of increased sympathetic neural activity
due to cardiac glycoside action within the central nervous
system . For instance, Helke et al. (2) found that toxic doses
of dcslanoside increased the concentration of a norepineph-
rine metabolite, and midcollicular decerebration increased
the dose of deslanoside required to trigger ventricular ar-
rhythmias. Similarly, Lathers et at. (3) reported that the
dose of ouabain needed to produce ventricular arrhythmias
in cats increased 2 weeks after sympathectomy. On the basis
of these studies, it could be anticipated that dopaminergic
agonists, which are known to decrease sympathetic neural
outflow (14-17) , would be useful for treatment of ventric-
ular tachyarrhythmias in the setting of cardiac glycoside
toxicity .
Site of action of bromocriptine in ouabain toxic-
ity. Our findings suggest a central site of action of brom-
ocriptinc in reversal of ouabain-induced ventricular tachy-
cardia . These observations differ from the findings of Falk
et at. (12) during studies of the effect of bromocriptine on
electrically induced ventricular fibrillation threshold in dogs .
In the latter study, both peripheral (domperidone) and com-
bined central and peripheral (haloperidol) dopaminergic re-
ceptor antagonists abolished the increase of ventricular fi-
brillation threshold induced by bromocriptine administration
alone. Presumably, the differences between our findings and
those of Falk et at. (12) are the result of the differing ven-
tricular tachyarrhythmia models used .
Side effects of bromocriptine administration. Two
unde sirable side effects occurred during bromocriptine
administration in this study. Brornocriptine induced a de-
crease in mean systemic pressure of approximately 50 mm
Hg, a characteristic that may be clinically undesirable, es-
pecially in patients with low blood pressure or reduced car-
diac output due to ventricular tachycardia . In addition , in
two lightly anesthetized dogs, bromocriptine administration
was associated with a transient period of vomiting. This
side effect is characteristic of other dopaminergic agonists,
such as apomorphine (I ,18), but in the case of bromocriptine
can be prevented by concomitant domperidone administra-
tion without altering the beneficial central nervous system
action of bromocriptine ( 19). However, as was found in our
study. domperidone does not supppress the hypotensive ac-
tions of bromocriptine .
Clinical implications. Currently, therapy of digitalis-
induced ventricular tachyarrhythmias consists primarily of
digitalis withdrawal along with the use of conventional an-
tiarrhythmic agents (for example , phenytoin and lidocaine)
and beta-adrenergic blocking drug s (20). Specific immu-
nologic therapy with Fah fragments (20.21) is promi sing.
but is not yet widely available . Our findings provide an
additional potentially useful therapeutic avenue for control
of these arrhythmias . Specifically , administration of dopa-
minergic agonists, such as bromocriptine , may become a
useful adjunct to present treatment methods . However , given
the delayed onset of brornocriptine 's action in this study,
the fact that termination of tachycardia was not achieved in
all dogs, and that hypotension was associated with brorn-
ocriptine administration, careful attention must yet be given
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to optimizing dose schedules and minimizing potential side
effects before clinical use in human subjects can be
recommended.
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